PD-L1

[Journal of Clinical Investigation] The authors reported that targeting of HIF-1α suppressed PD-L1 expression on tumor cells and tumor-infiltrated myeloid cells, but unexpectedly induced PD-L1 in normal tissues by an IFNγ–dependent mechanism.

[Future Oncology] The authors take stock of the relationship between epidermal growth factor receptor (EGFR) mutations and PD-1 and its ligand receptor 1expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.

[Scientific Reports] Mechanistic insights demonstrated that blockade of the PD-1 axis decreased stem-like marker ALDH and expression of DNA repair genes.

[Scientific Reports] Researchers generated thymus-complemented chimeric mice, assessed the efficacy of anti-PD-L1 antibody in tumor-bearing chimeric mice, and then investigated T cell function.

[Communications Biology] Researchers used a humanized mouse model to show that while carboplatin plus pembrolizumab reduced tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2, delivered systemically in nanovesicles, to this combination, eradicates tumors in the majority of animals.

[Science Advances] Scientists explored the therapeutic potential of targeting PTPN2 in TNBC and T cells. PTPN2-deficiency in TNBC associated with T cell infiltrates and PD-L1 expression, whereas low PTPN2 associated with improved survival.